Insurers won't cover new Alzheimer's treatment Leqembi for some customers
Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer's patients.
Stay updated with breaking news from Greg Warren. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer's patients.
Their decision stands in contrast to Medicare, which will wind up covering most patients who take the drug.
Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer's patients.
Insurers Won't Cover New Alzheimer's Treatment For Some Customers - Across America, US - Patients who don't get coverage through a commercial plan may eventually receive it through government programs. But waiting is risky.
Their decision stands in contrast to Medicare, which will wind up covering most patients who take the drug.